Report Overview

The global injectable drug delivery market was pegged at US$ 546.07 billion in 2021 and is expected to witness a CAGR of 13% during the forecast period from 2022 to 2030.

Market Fundamentals                                                                                          

The injectable drug delivery system is a deem technique for drug delivery and provides high efficiency in delivering the medications to the patient, thus providing faster and better outcomes. The intravenous and intramuscular offers fasters absorption of the drugs using injecting method. The injectable administration boosts the drug's bioavailability in systemic circulation, providing accessibility to the medication at its targeted site of action.

[789754]

Market Dynamics

The injectable drug delivery market itself is a very big market and is estimated to grow rapidly in the forecast period. The growth of this market can be attributed to the growing prevalence of chronic disease, increasing surgical procedures, and rising adoption of injections. Additionally, increased use of biologics, growing R&D activities, and rapid launch of advanced technologies further contribute to the market expansion. Further development in healthcare infrastructure and rising urbanizt policies for devices & products and the high cost of devication can also be considered a driving trend in the market. However, the lack of reimbursemenes are some major challenges in the market.

Market Ecosystem

The global injectable drug delivery market has been analyzed from four perspectives: by device type, product type, end-user, and region. 

Injectable Drug Delivery Market by Type

[8986575]

Based on type, the global injectable drug delivery market has been bifurcated into conventional injectables, auto-injectors, pre-filled syringes, and pen injectors. Conventional injectables lead the segment with the largest revenue share owing to rising incidences of chronic or infectious diseases, increasing medical consultation, and growing demand for syringes. Furthermore, Covid-19 also influenced the growth of the market due to increased vaccination programs.

Injectable Drug Delivery Market by Application

Based on the application, the global injectable drug delivery market has been segmented into injectable sterile and freeze-dried products. The injectable sterile products segment is dominant owing to its quality assurance and storability property. Sterile products are generally preferred in hospitals and clinics by surgeons during surgeries and treating complex diseases. The injectable sterile are pathogen-free and thus pose a lower risk of infections, aiding the expansion of this segment in the market. But the freeze-dried products segment is anticipated to grow faster during the forecast period. The innovative product type has been extensively preferred to improve the bioavailability of the drug to be injected and patient compliance. Demand for freeze-dried products is likely to increase due to its advantage of delivering stabilized formulations.

Injectable Drug Delivery Market by End User

Based on end-user, the injectable drug delivery market has been segmented into hospitals, clinics, ambulatory surgical centers, home care settings, and others. The hospitals and clinics segment holds the largest revenue share in this market. It is expected to show constant dominance in the forecast period. This facility connects the healthcare system and manufacturers through electronic or digital platforms. Emerging demand for drugs and medical devices due to growing chronic disease prevalence and COVID-19 pandemic factor has positively impacted the market growth. This method can also address the desired requirements of various drugs and devices, further boosting the market growth globally. 

Injectable Drug Delivery Market by Region

Geographically, the global injectable drug delivery market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominates the global injectable drug delivery market with the largest revenue share. Constant innovations & advancements in technologies, developed healthcare infrastructure, and a high geriatric population attribute to the market growth in this region. Additionally, increased chronic disease prevalence, surgical procedures, and continuous research and development initiatives further drive market growth. While Europe holds the second largest revenue share in the market owing to the high adoption of heightened technologies, advanced healthcare infrastructure, and increase in chronic disease prevalence.

Asia Pacific is also considered the fastest-growing region in this market. This growth can be attributed to the increasing adoption of technologies, the developing healthcare infrastructure, and improving medical tourism. Furthermore, the large base for the aged population and an expanding patient pool in this region are also some driving factors in the injectable drug delivery market in Asia Pacific.

Competitive Landscape

Some of the prominent players operating in the global injectable drug delivery market are: 

• Schott AG
• Elcam Medical ACS. Ltd
• Baxter International Inc.
• Eli Lilly and Company
• Gerresheimer AG
• Pfizer Inc.
• Ypsomed AG
• SHL Medical AG
• Insulet Corporation
• West Pharmaceutical Services Inc.
• Teva Pharmaceuticals Industries Ltd.
• B. Braun Melsungen AG

Strategic Developments

• In April 2020, Teva Canada, launched a novel autoinjector for AJOVY. AJOVY is a subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month.
• In March 2020, Becton, Dickinson and Company (BD) completed the 50-human clinical trial of their newly launched injectable drug delivery device namely the BD Libertas Wearable Injector. 
•  

Frequently Asked Questions About This Report